CA2964114A1 - Placenta-derived adherent cell exosomes and uses thereof - Google Patents

Placenta-derived adherent cell exosomes and uses thereof Download PDF

Info

Publication number
CA2964114A1
CA2964114A1 CA2964114A CA2964114A CA2964114A1 CA 2964114 A1 CA2964114 A1 CA 2964114A1 CA 2964114 A CA2964114 A CA 2964114A CA 2964114 A CA2964114 A CA 2964114A CA 2964114 A1 CA2964114 A1 CA 2964114A1
Authority
CA
Canada
Prior art keywords
placenta
derived adherent
exosomes
adherent cell
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2964114A
Other languages
English (en)
French (fr)
Inventor
Eric Law
Andrew MORSCHAUSER
Aleksandar Francki
Jennifer Paredes
Kathy E. Karasiewicz-Mendez
Allan REDUTA
Vladimir Jankovic
Ivana DJURETIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celularity Inc
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55653751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2964114(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of CA2964114A1 publication Critical patent/CA2964114A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2964114A 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof Pending CA2964114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062046P 2014-10-09 2014-10-09
US62/062,046 2014-10-09
PCT/US2015/054629 WO2016057755A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof

Publications (1)

Publication Number Publication Date
CA2964114A1 true CA2964114A1 (en) 2016-04-14

Family

ID=55653751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964114A Pending CA2964114A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof

Country Status (8)

Country Link
US (3) US20170252379A1 (https=)
EP (1) EP3204022B1 (https=)
JP (3) JP2017536096A (https=)
CN (2) CN107106615A (https=)
AU (2) AU2015330855A1 (https=)
CA (1) CA2964114A1 (https=)
DK (1) DK3204022T3 (https=)
WO (1) WO2016057755A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
EP3307890A1 (en) 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
JP2019514416A (ja) * 2016-05-16 2019-06-06 エグゾステム バイオテック リミテッド 間葉系幹細胞と筋損傷及び筋肉関連疾患の治療のための間葉系幹細胞の使用
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2018208702A1 (en) * 2017-05-09 2018-11-15 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
CA3064064A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
JP7399712B2 (ja) * 2017-05-24 2023-12-18 ナノソミックス・インコーポレイテッド 疾病および障害の診断および予後判定のための小胞上のバイオマーカーの検出
KR102109950B1 (ko) * 2017-06-02 2020-05-12 (주)엑솔런스바이오테크놀로지 체외충격파를 이용한 세포외소포체 내로의 표적물질 전달방법
IL272786B2 (en) 2017-08-25 2025-03-01 Codiak Biosciences Inc Preparation of therapeutic exosomes using membrane proteins
KR102335710B1 (ko) * 2017-10-31 2021-12-07 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
GB201718681D0 (en) * 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
MX2020005100A (es) * 2017-11-16 2020-11-24 Celularity Inc Cultivo de placenta para aislar exosomas.
US12036325B2 (en) 2017-12-14 2024-07-16 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
CN111655271B (zh) 2017-12-28 2025-09-23 隆萨销售股份公司 用于免疫肿瘤学和抗炎疗法的外来体
US20210038652A1 (en) * 2018-01-30 2021-02-11 Histogen, Inc. Extracellular vesicles derived from cells cultured under hypoxic conditions and uses thereof
KR102235141B1 (ko) * 2018-06-19 2021-04-05 푸와이 하스피틀, 차이니즈 아카데미 오브 메디컬 사이언시즈 앤드 페킹 유니언 메디컬 칼리지 약물 전처리에 기초한 간엽 줄기세포 유래 엑소좀 제조방법
JP2021531828A (ja) * 2018-07-24 2021-11-25 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 細胞外小胞を形質転換することを伴う組成物及び方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109554341B (zh) * 2018-12-18 2021-11-19 深圳先进技术研究院 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用
CN110093274B (zh) * 2019-05-13 2020-08-11 山东大学 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用
CA3142020A1 (en) * 2019-06-19 2020-12-24 Celularity Inc. Exosomes for disease treatment
WO2021210852A1 (ko) * 2020-04-14 2021-10-21 (주)녹십자웰빙 태반 유래 물질을 포함하는 항바이러스 조성물
KR20220030552A (ko) * 2020-09-03 2022-03-11 (주)녹십자웰빙 태반 유래 엑소좀을 포함하는 간세포 증식 또는 항염증 효능 조성물
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ
WO2024102969A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Use of fecal derivatives and fecal derived extracellular vesicles to enhance immunity
CN117050936A (zh) * 2023-07-11 2023-11-14 清华大学 新亚群的人脐带间充质干细胞、其外泌体、制剂和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316919B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
WO2010021715A1 (en) 2008-08-20 2010-02-25 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
CN105708862B (zh) * 2008-09-02 2020-11-06 普拉里斯坦有限公司 来自胎盘组织的粘附细胞及其在治疗中的用途
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
FR2950360B1 (fr) * 2009-09-22 2011-11-25 Centre Nat Rech Scient Procede d'imagerie cellulaire pour la visualisation de la biogenese des microarns dans les cellules
LT2556145T (lt) * 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
AU2012236099A1 (en) * 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP2014519340A (ja) * 2011-06-16 2014-08-14 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
JP6029112B2 (ja) * 2011-12-22 2016-11-24 テオリアサイエンス株式会社 エクソソームの分析方法、エクソソーム分析用試薬およびエクソソーム分析装置
US9427450B2 (en) * 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
EP3563859B1 (en) * 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP3031921B1 (en) * 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
AU2013361323B2 (en) * 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
EP3608022A1 (en) * 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification

Also Published As

Publication number Publication date
WO2016057755A1 (en) 2016-04-14
EP3204022A4 (en) 2018-06-13
CN107106615A (zh) 2017-08-29
CN116731958A (zh) 2023-09-12
DK3204022T3 (da) 2021-03-08
US20170252379A1 (en) 2017-09-07
AU2015330855A1 (en) 2017-04-27
EP3204022A1 (en) 2017-08-16
EP3204022B1 (en) 2020-12-02
JP2021040635A (ja) 2021-03-18
JP2023011580A (ja) 2023-01-24
US11173182B1 (en) 2021-11-16
US20220241347A1 (en) 2022-08-04
JP2017536096A (ja) 2017-12-07
AU2021204332A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
US11173182B1 (en) Placenta-derived adherent cell exosomes and uses thereof
US20220096560A1 (en) Methods and compositions relating to mesenchymal stem cell exosomes
JP6716564B2 (ja) 安定したエクソソーム製剤の製造方法
US9877989B2 (en) Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
AU2022291415A1 (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
JP2022538004A (ja) 疾患治療用エキソソーム
WO2023164241A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
US20220362341A1 (en) Treatment of major depressive disorder by low dose interleukin-2
US20210308186A1 (en) Treatment of Acute Respiratory Distress Syndrome by T Regulatory Cells
US20230141224A1 (en) Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
HK1242969B (en) Placenta-derived adherent cell exosomes and uses thereof
HK1242969A1 (en) Placenta-derived adherent cell exosomes and uses thereof
EP4123019A1 (en) Cord blood plasma-derived exosome or mimetic thereof and pharmaceutical use thereof
AU2022294095A1 (en) Fibroblast based therapeutics of amyotrophic lateral sclerosis
HK1241290A1 (en) Placenta-derived adherent cell exosomes and uses thereof
US12011462B2 (en) Stimulation of mesenchymal stem cell therapeutic activities by T regulatory cells
US20230364143A1 (en) Protection from ovarian failure by low dose interleukin-2 administration
US20230365930A1 (en) Immunological enhancement of stem cell activity in treatment of ovarian failure
JP2022551916A (ja) 新規調節性マクロファージ及びその使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200924

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251107

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: N-6-6-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260421

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260421